Abstract: Provided is an authentication apparatus capable of appropriately performing personal authentication. An authentication apparatus (40) according to the present disclosure includes: an acquisition unit (41) configured to acquire authentication information that is second biometric information of a user who has succeeded in biometric authentication using first biometric information, and is second biometric information capable of being acquired by an instrument that has acquired the first biometric information; a comparison unit (43) configured to compare collation information registered in advance with the authentication information; and an authentication unit (44) configured to perform personal authentication of the user on the basis of a result of the comparison.

Abstract: An object is to provide a digital asset management apparatus capable of appropriately managing a digital asset. A digital asset management apparatus (10) according to the present disclosure includes: a registration unit (11) that registers agent information of an agent with respect to member information of a member having an account; a first transmission unit (12) that transmits a confirmation notice to the member in a case where there is no access for a setting period set by the member or more; a second transmission unit (13) that transmits an agent notice to the agent in a case where there is no member response; an authentication control unit (14) that controls authentication of the agent in a case where there is an agent response; and an authorization unit (15) that gives the agent authority related to a digital asset when the authentication is successful.

Abstract: The present invention provides a method for determining a sodium lauryl sulfate having a desired quality as a pharmaceutical raw material for a formulation by detecting a slight difference in quality of sodium lauryl sulfate to be used as a pharmaceutical raw material for a formulation. The present invention relates to a method for sorting a raw material for a formulation which can provide a pharmaceutical formulation excellent in stability by pretreating the material for a formulation under a predetermined accelerated condition and detecting an impurity. According to the method of the present invention, it is possible to determine the quality of sodium lauryl sulfate of a pharmaceutical raw material for a formulation having no effect on the quality of a pharmaceutical formulation containing alectinib or a salt thereof.

Abstract: An amorphous form of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile and a solid dispersion containing the amorphous form can be used extremely advantageously as drugs for oral administration.

Abstract: An amorphous form of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile and a solid dispersion containing the amorphous form can be used extremely advantageously as drugs for oral administration.

Abstract: An amorphous form of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile and a solid dispersion containing the amorphous form can be used extremely advantageously as drugs for oral administration.

Abstract: An amorphous form of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile and a solid dispersion containing the amorphous form can be used extremely advantageously as drugs for oral administration.

Abstract: An amorphous form of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile and a solid dispersion containing the amorphous form can be used extremely advantageously as drugs for oral administration.

Abstract: An amorphous form of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile and a solid dispersion containing the amorphous form can be used extremely advantageously as drugs for oral administration.